HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prophylactic Dose of Dalteparin in Pregnant Women With History of Venous Thromboembolisms and/or Thrombophilia: Real-World Data.

Abstract
Women with a history of venous thromboembolisms (VTEs) and/or thrombophilia are at increased risk of VTE during pregnancy. We analysed our cohort of such women who were treated with a prophylactic doses of dalteparin. 152 pregnant women with 179 pregnancies were classified into 3 groups: (1) previous VTE without thrombophilia (122 pregnancies); (2) previous VTE with thrombophilia (26 pregnancies) and (3) thrombophilia only (31 pregnancies). They were treated with prophylactic dalteparin in the prepartum and postpartum periods or only in the postpartum period. Occurrences of symptomatic VTE and bleeding episodes were followed, as well as dalteparin discontinuation and anti-Xa activity. Symptomatic deep vein thrombosis occurred in 4 women (2.2%) with 2 episodes in group 1 (in the postpartum period) and 2 episodes in group 2 (one in the prepartum and another in the postpartum period). Seven episodes (3.9%) of minor bleeding occurred. Dalteparin was not stopped in any women. Anti-Xa levels were within the prophylactic range. Our real-world data show a low incidence of thrombosis and minor bleeding in pregnant women treated with prophylactic dalteparin. The incidence of recurrent VTE was lower than that reported in women with similar risk, but without prophylactic anticoagulation.
AuthorsPetra Novak, Anja Novak, Mišo Šabović, Matija Kozak
JournalAngiology (Angiology) Vol. 74 Issue 8 Pg. 783-789 (09 2023) ISSN: 1940-1574 [Electronic] United States
PMID36113126 (Publication Type: Journal Article)
Chemical References
  • Dalteparin
  • Heparin, Low-Molecular-Weight
  • Anticoagulants
Topics
  • Female
  • Humans
  • Pregnancy
  • Dalteparin (adverse effects)
  • Venous Thromboembolism (epidemiology)
  • Pregnant Women
  • Risk Factors
  • Venous Thrombosis
  • Heparin, Low-Molecular-Weight (therapeutic use)
  • Thrombophilia (complications, drug therapy, chemically induced)
  • Hemorrhage (chemically induced)
  • Anticoagulants (adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: